ResMed Inc (RME.HA)
Hanover - Hanover Delayed price. Currency in EUR
Add to watchlist
At close: 08:00AM CEST
| Previous close | 173.80 |
| Open | 173.40 |
| Bid | 178.95 x N/A |
| Ask | 180.35 x N/A |
| Day's range | 173.40 - 173.40 |
| 52-week range | 127.55 - 202.30 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 01 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2024 on Thursday, August 1, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location: http://investor.resmed.com Date:
ZacksOmnicell (OMCL) Banks on Product Launches, Global Growth
Omnicell (OMCL) remains a key player in automating and modernizing global medication management infrastructure.
ZacksZacks.com featured highlights include ResMed, Badger Meter, Leidos and Ingersoll Rand
ResMed, Badger Meter, Leidos and Ingersoll Rand are part of the Zacks Screen of the Week article.
© 2024 Yahoo. All rights reserved.